456 Studies Now Enrolling
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED ORMETASTATIC HEPATOCELLULAR CARCINOMA
Study of Atezolizumab and Bevacizumab Alone or in Combination with Tiragolumab in Patients with Hepatocellular Carcinoma (HCC)
| Sponsor: | F. HoffmannLa-Roche Ltd |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAU7689 |
| U.S. Govt. ID: | NCT05904886 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this study, participants will be randomized you will get either tiragolumab plus atezolizumab plus bevacizumab or placebo plus atezolizumab plus bevacizumab. A placebo looks like a drug but has no active ingredient. Tiragolumab has not been approved by FDA to treat HCC. Atezolizumab plus bevacizumab is currently the standard of care.
